8-K current report · filed Apr 23, 2026

Tectonic Therapeutic, Inc. (TECX) 8-K Current Report: April 23, 2026

Item 5.02Item 7.01Item EX-99.1TECX overview

Short answer

Tectonic Therapeutic, Inc. (TECX) filed an 8-K current report with the SEC on April 23, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Jessica Chutter appointed independent Class III director effective 2026 Annual Meeting, with term expiring at 2027 annual meeting.

Tectonic Therapeutic, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Jessica Chutter appointed independent Class III director effective 2026 Annual Meeting, with term expiring at 2027 annual meeting
  • Audit Committee appointment strengthens board oversight and satisfies Nasdaq independence requirements
  • Annual compensation totals $47,500 cash: $40,000 board retainer plus $7,500 Audit Committee fee
  • Initial equity award: options for 20,400 shares, with one-third vesting after one year and remainder monthly through year three
  • Equity awards accelerate fully immediately before a 2024 Plan-defined change in control if she remains on the Board

Item 7.01 · Regulation FD Disclosure

  • Exhibit 99.1 furnished under Regulation FD rather than filed under Exchange Act Section 18
  • Reduced liability and incorporation-by-reference exposure for the disclosed information
  • Investors should review Exhibit 99.1 for the substantive disclosure associated with this filing

Item EX-99.1 · Exhibit EX-99.1

  • Jessica Chutter appointed director effective June 8, 2026, adding senior biotechnology capital-markets expertise
  • Former Morgan Stanley executive involved in approximately $80 billion of financings and $85 billion of strategic transactions
  • Board addition may support future fundraising, partnerships, and M&A as Tectonic advances two clinical programs across three indications
  • Chutter’s simultaneous PTC Therapeutics directorship creates relevant industry connectivity but potential governance oversight considerations

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Tectonic Therapeutic, Inc. 8-K filings

Get the next TECX 8-K as it lands

Follow TECX for push alerts, or ask the research agent what this filing means.